Watch CEO Dr Michael Thurn’s February 2024 investor update.

pharmaus 210

OUR COMPANY

PharmAust is a clinical-stage biotechnology company developing new therapeutics for human and animal health applications. The company is repurposing monepantel for the treatment of cancer in dogs and neurodegenerative diseases in humans.

Read more

pharmaust research

OUR SCIENCE

Monepantel is an approved veterinary product for the treatment of nematode infestations in sheep. In mammalian cells, monepantel is a potent inhibitor of the mTOR pathway. The mTOR pathway plays a central role in cell growth and proliferation of cancer cells.

Read more

Explore the Newest Video Content from PharmAust (PAA) Right Here!